Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22229650 | 1.00 | ROCK2 (0.43) | ROCK2ROCK1NOS3NOS1NOS2 | |
| SCHEMBL28451045 | 0.92 | ROCK2 (0.48) | ROCK2ROCK1NOS3NOS1NOS2 | |
| SCHEMBL30189442 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1DYRK1A | |
| SCHEMBL22229560 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1DYRK1A | |
| SCHEMBL22229637 | 0.89 | ROCK2 (0.46) | ROCK2ROCK1DYRK1APDE10ATIPARP | |
| SCHEMBL30189500 | 0.89 | ROCK2 (0.46) | ROCK2ROCK1DYRK1APDE10ATIPARP | |
| SCHEMBL30189613 | 0.87 | MGLL (0.35) | ROCK2ROCK1NOS1NOS2 | |
| SCHEMBL22229569 | 0.87 | MGLL (0.35) | ROCK2ROCK1NOS1NOS2 | |
| SCHEMBL22229605 | 0.86 | GRM4 (0.39) | ROCK2ROCK1HCRTR1HCRTR2KDM1A | |
| SCHEMBL22229629 | 0.86 | ROCK2 (0.38) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ANGION BIOMEDICA CORP. (US) | 2023-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885NOS3 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.